Skip to main content

Moderna, Inc. United States revenue

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

United States revenue at Moderna, Inc. came to $1.2B for the fiscal year to 31 Dec 2025, down 32.8% from a year earlier.

As Moderna, Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 20 Feb 2026.

By fiscal year

$89.1MDec 2018$55.0MDec 2019$764.0MDec 2020$6.2BDec 2021$5.2BDec 2022$1.9BDec 2023$1.8BDec 2024$1.2BDec 2025
Moderna, Inc. United States revenue, every reported period
Period endingUnited States revenueChange on a yearFiled
31 Dec 2025$1.2Bdown 32.8%20 Feb 2026
31 Dec 2024$1.8Bdown 5.8%21 Feb 2025
31 Dec 2023$1.9Bdown 63.2%23 Feb 2024
31 Dec 2022$5.2Bdown 16.6%24 Feb 2023
31 Dec 2021$6.2Bup 708.5%25 Feb 2022
31 Dec 2020$764.0Mup 1289.1%26 Feb 2021
31 Dec 2019$55.0Mdown 38.3%27 Feb 2020
31 Dec 2018$89.1M—13 Mar 2019

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Moderna, Inc.: COVID revenue · Stand-ready manufacturing revenue · RSV revenue · Collaboration Arrangement, Including Arrangements With Affiliate revenue · Grant revenue · Rest of world revenue · Europe revenue · financial statements

Every KPI and segment of MRNA, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.